Cen Biotech Inc CENBF
We take great care to ensure that the data presented and summarized in this overview for CEN BIOTECH INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CENBF
Top Purchases
Top Sells
About CENBF
CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. It intends to cultivate hemp for usage in industrial, medical, and food products; and to provide digital marketing and web design related services. The company was incorporated in 2013 and is based in Windsor, Canada.
Insider Transactions at CENBF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 06
2021
|
Rick Leigh Purdy SVP of Deals and Acquisitions |
BUY
Grant, award, or other acquisition
|
Direct |
2,500,000
+47.09%
|
-
|
|
Jun 25
2021
|
Alex Tarrabain Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+26.48%
|
-
|
|
Jun 16
2021
|
Alex Tarrabain Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
3,000
+0.11%
|
-
|
|
May 16
2021
|
Alex Tarrabain Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
3,000
+0.17%
|
-
|
|
Apr 16
2021
|
Alex Tarrabain Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
3,000
+0.17%
|
-
|
|
Apr 10
2021
|
Alex Tarrabain Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
30,000
+1.66%
|
$30,000
$1.6 P/Share
|
|
Apr 02
2021
|
Donald Strilchuck Director |
BUY
Grant, award, or other acquisition
|
Direct |
341,250
+20.04%
|
-
|
|
Apr 02
2021
|
De Lavenu Harold Andre Aubrey Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,041,250
+39.07%
|
-
|
|
Apr 02
2021
|
Alex Tarrabain Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+14.47%
|
-
|
|
Apr 02
2021
|
Ameen Ferris Vice President* |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+49.51%
|
-
|
|
Apr 02
2021
|
Bahige B. Chaaban Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,106,122
+22.02%
|
-
|
|
Apr 02
2021
|
Brian Payne Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
1,435,000
+39.38%
|
-
|
|
Apr 02
2021
|
Richard Boswell Senior Executive VP |
BUY
Grant, award, or other acquisition
|
Direct |
2,185,679
+26.7%
|
-
|
|
Apr 02
2021
|
Usamakh Saadikh Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+49.51%
|
-
|
|
Mar 16
2021
|
Alex Tarrabain Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
3,000
+0.17%
|
-
|
|
Feb 16
2021
|
Alex Tarrabain Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
3,000
+0.17%
|
-
|
|
Jan 27
2021
|
Richard Boswell Senior Executive VP |
SELL
Open market or private sale
|
Direct |
6,250
-0.1%
|
$0
$0.8 P/Share
|
|
Jan 26
2021
|
Richard Boswell Senior Executive VP |
SELL
Open market or private sale
|
Direct |
37,500
-0.62%
|
$0
$0.4 P/Share
|
|
Jan 16
2021
|
Alex Tarrabain Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
3,000
+0.17%
|
-
|